Eisai CoESALF 74 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $36.60 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 685 Drug Manufacturers companies, Eisai Co ranks worse than 58.54% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Eisai Co's
Operating Income
for the
three
months ended in Mar. 2026 was $-65 Mil. Eisai Co's Interest Expense for the
three
months ended in Mar. 2026 was $-10 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Eisai Co's Interest Coverage or its related term are showing as below:
ESALF'
s Interest Coverage Range Over the Past 10 Years
Min: 8.27 Med: 24.2 Max: 85.84
Current: 8.27
ESALF's Interest Coverage is ranked worse than 58.54% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs ESALF: 8.27
Eisai Co (OTCPK:ESALF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Eisai Co Interest Coverage Related Terms
Eisai Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Eisai Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Eisai Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Eisai Co did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Eisai Co (ESALF) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Eisai Co and its competitors. Over the past decade, Eisai Co's Interest Coverage has ranged from 8.27 to 85.84. According to the industry distribution chart, Eisai Co ranks #401 out of 685 companies in the Drug Manufacturers industry, placing it in the top 58.5%.
Is Eisai Co's Interest Coverage too high?
Eisai Co's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 8.27 to a high of 85.84. Based on the distribution chart, Eisai Co ranks #401 out of 685 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #401 out of 685 companies for Interest Coverage. This places Eisai Co in the lower half of its industry. The industry median Interest Coverage is 12.78. Historically, Eisai Co's own Interest Coverage has ranged from 8.27 to 85.84 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Significantly Undervalued. The stock's GF Value™ is $36.60, compared to a current price of $25.00 — trading 31.7% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Eisai Co (ESALF), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 31.7% below its estimated GF Value™ of $36.60.
GuruFocus considers Eisai Co to be Significantly Undervalued.
Key valuation signals for ESALF:
Interest Coverage: 0 (At Loss)
GF Value™: $36.60 vs. price of $25.00 (31.7% below fair value)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for ESALF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
